Lyme: The Infectious Disease Equivalent of Cancer, Says Top Duke Oncologist
Last week, I mentioned the case of Dr. Neil Spector, whose long-undiagnosed Lyme Disease resulted in irreversible heart failure and ultimately, a heart transplant. Dr. Spector, author of Gone in a Heartbeat: A Physician's Search for True Healing, is the Sandra Coates Associate Professor of Medicine and Associate Professor of Pharmacology and Cancer Biology at Duke University School of Medicine. As the Director of Developmental Therapeutics at the Duke Cancer Institute, he's a leader in applying translational research to the clinical development of molecularly targeted personalized cancer therapies. Here, Dr. Spector shares his story, explains what Lyme and cancer have in common (hint: a LOT), and encourages us with his vision for the future. Like so many of us, your Lyme was missed by multiple physicians. What were your symptoms? I don't recall a tick bite, but I first started having symptoms in 1993, mostly cardiac arrhythmias. I had unprovoked palpitations that lasted fifteen to twenty seconds. There was something ominous about the way they felt and came on, but they were never captured because by the time I got to the ER, they'd resolve. And because I had just moved to a new state and was extremely busy with my career, the easy diagnosis was that I was just stressed. Doctors were saying I looked and seemed fine, but I wasn't. I also had an early episode of brain fog that came on out of the blue. I gave a lecture at University of Miami School of Medicine for an hour, and...
Foods high in soluble fiber like oatmeal, nuts and beans were associated with reduced breast cancer incidence.
Publication date: Available online 4 April 2020Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Kaili Wang, Weijie Zhang, Zihan Wang, Ming Gao, Xinying Wang, Wenchao Han, Nan Zhang, Xia Xu
Publication date: Available online 5 April 2020Source: Seminars in Cancer BiologyAuthor(s): Emad A. Rakha, Fresia G. Pareja
Publication date: Available online 4 April 2020Source: Seminars in Cancer BiologyAuthor(s): Michela Biancolella, Barbara Testa, Leila Baghernajad Salehi, Maria Rosaria D’Apice, Giuseppe Novelli
Publication date: Available online 4 April 2020Source: Seminars in Cancer BiologyAuthor(s): Jyoti Gupta, Haaris Ahsan Safdari, Mehboob Hoque
Publication date: Available online 5 April 2020Source: Anaesthesia Critical Care &Pain MedicineAuthor(s): Alexandre Joosten, Sean Coeckelenbergh, Brenton Alexander, Maxime Cannesson, Joseph Rinehart
CONCLUSION: Here, we present what, to the best of our knowledge, is the first reported case in which durvarumab resistance after definitive chemoradiotherapy in a patient with stage III pulmonary sarcomatoid carcinoma was overcome by pembrolizumab. PMID: 32245391 [PubMed - as supplied by publisher]
UK-based biopharma company Izana Bioscience said it was testing its antibody therapy namilumab for the treatment of patients with rapidly worsening COVID-19 at the Humanitas Research Hospitals in Bergamo and Milan in Italy.
British Journal of Cancer, Published online: 06 April 2020; doi:10.1038/s41416-020-0822-xCombining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma
More News: Allergy & Immunology | Alzheimer's | Antibiotic Therapy | Arrhythmia | Arthritis | Autoimmune Disease | Benadryl | Biology | Borrelia | Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Cardiac Arrhythmia | Cardiology | Cervical Cancer | Chemotherapy | Doxycycline | Drugs & Pharmacology | Fibromyalgia | Gastric (Stomach) Cancer | Head and Neck Cancer | Heart | Heart Failure | Heart Transplant | Helicobacter Pylori | Infectious Diseases | Laboratory Medicine | Lupus | Lyme Disease | Lymphoma | Melanoma | Men | Molecular Biology | Neurology | Neuroscience | Nightmares | Rheumatoid Arthritis | Rheumatology | Science | Skin Cancer | Study | Syphilis | Transplant Surgery | Transplants | Websites